How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus

Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes mellitus. Hemoglobin A1c >6.5% and <10%. Estimated GFR greater than 60 mL per minute per meter squared. Between 18 and 70 years of age. On oral antihyperglycemic agents with stable dose at least for last 2 months. Females: minimum of two years postmenopausal, surgically sterile, or using an acceptable contraceptive regimen (OCP, IUD, double barrier, Depo-Provera or subcutaneous progestin implant) and negative urine pregnancy test at trial start

2015 Clinical Trials

282. Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

;History of previous IUD complications, such as perforation, expulsion, infection (pelvic inflammatory disease) or pregnancy with IUD in place; History of previous serious IUD complications; Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months; 6.1 Must have had 2 normal menstrual cycles since the last injection; Planned use of any non-contraceptive estrogen, progesterone or testosterone any time during the 12 months of study participation; Postpartum, prior to a minimum

2015 Clinical Trials

283. Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

contraceptives, contraceptive patches/rings/implants Norplant, Depo-Provera, double-barrier methods (e.g. condoms and spermicide) and abstinence. Subjects willing to refrain from the use of topical products containing alpha-hydroxy acids, retinoic acid, retinol, salicylic acid, and vitamins C/D (or their derivatives) in the treatment area 7 Days prior to and during the entire study period Exclusion Criteria: Known hypersensitivity, prior allergic reaction, or prior chest treatment with ingenol mebutate gel

2015 Clinical Trials

284. A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product

), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner BMI 18-29.9 kg/m2 (±1 kg/m2) Healthy as determined by laboratory results and medical history Agrees to maintain current level of physical activity throughout the study Agree to avoid using black or white pepper, turmeric, curcumin or curry in the preparation of food for 7 days prior to randomization and throughout the study period. Agree

2015 Clinical Trials

285. Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Childern Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs)

), or regular medroxyprogesterone injections (Depo-Provera®); or (b) Patient agrees to initiate sexual abstinence from the time of screening until 7 days after end of treatment with study drug; and (ii) Patient is advised to avoid conception from the time of screening until 7 days after receipt of study drug and agrees not to attempt pregnancy from the time of screening until 7 days after end of treatment with study drug; and (iii) Patient is provided guidelines regarding continuation of abstinence

2015 Clinical Trials

286. Trial of pIL-12/MK-3475 in Metastatic Melanoma

(for example, hormone pills, hormone rings, hormone patches, hormone-releasing IUDs, or Depo Provera). Men with partners who are capable of getting pregnant must agree to use one of the barrier methods of contraception listed above during participation in the study, starting with the first dose of study drug through 120 days after the last dose of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating

2015 Clinical Trials

287. Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

an acceptable form of birth control from the day of the first dose administration to 30 days after the last administration of IP. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (Medroxyprogesterone acetate- stabilized for at least 3 months); vaginal contraceptive; contraceptive implant; double barrier methods (e.g. condom and spermicide); Nuvaring vaginal hormonal birth control, IUD

2015 Clinical Trials

288. Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

, birth control once monthly injections, condom or vaginal sponge with spermicide. Exclusion Criteria: Are female with amenorrhea for 3 consecutive months prior to screening, with the exception of women who are on Depo-Provera or oral contraceptives for the purpose of suppressing menstruation Has a current DSM-IV or DSM-V diagnosis other that schizophrenia including schizophreniform disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other

2015 Clinical Trials

289. Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

banded coil), levonorgestrel intrauterine system (eg, Mirena®), or regular medroxyprogesterone injections (Depo-Provera®); or (b) Patient agrees to initiate sexual abstinence from the time of screening until 7 days after end of treatment with study drug; and (ii) Patient is advised to avoid conception from the time of screening until 7 days after receipt of study drug and agrees not to attempt pregnancy from the time of screening until 7 days after end of treatment with study drug; and (iii) Patient

2015 Clinical Trials

290. BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study

is the primary focus of treatment Patients with mood congruent or mood incongruent psychotic features Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (e.g. oral contraceptives, intrauterine device, barrier methods, or total abstinence from intercourse; Depo Provera is acceptable if it is started 3 months prior to enrollment). Women who are nursing Patients who are a serious suicide or homicide risk Suspected or known clinically unstable

2015 Clinical Trials

291. The Effects of Acute Weight Gain and Acute Calorie Deprivation on Marrow Adipose Tissue

period Normal transaminase levels (AST/ALT) Exclusion Criteria: Any disease known to affect bone metabolism, including untreated thyroid dysfunction, Cushing's syndrome, or renal failure Any medication known to affect bone metabolism -- including systemic steroids or immunosuppressants -- within three months of the study, excluding estrogen and progestins. Patients receiving depot medroxyprogesterone (Depo-Provera) will be excluded from participating for six months after their last injections

2015 Clinical Trials

292. Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

). Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrel implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. Absolute Neutrophil Count

2015 Clinical Trials

293. A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

contraception during the study and for 30 days after the last study medication application. Females are considered to be of childbearing potential unless surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation), diagnosed as infertile, or are postmenopausal for at least 1 year; (Acceptable methods of birth control are defined as: abstinence, oral contraceptives, contraceptive patches/implants, Depo-Provera®, double barrier methods (e.g. condom and spermicide) or an intrauterine device

2015 Clinical Trials

294. The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis

, or intra-vaginal hormonal contraceptives Norplant System® Depo-Provera® IUD double barrier method abstinence surgically sterile females (hysterectomy or tubal ligation) > 1 year post-menopausal females same sex partner partner vasectomy (> 3 months) Participant is healthy as determined by pre-study medical history, physical examination and vital signs. Participant is able to read, comprehend, and record all information in English. Participant has a serum specific IgE level to both birch and timothy

2015 Clinical Trials

295. Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

and condom by partner condom and spermicide by partner intrauterine device and condom by partner sponge and condom by partner complete abstinence from sexual intercourse oral contraceptives, Depo-Provera, Norplant, Patch, and intrauterine progesterone contraceptive Be able to comply with protocol requirements, rules and regulations of the study site and be likely to complete all the study treatments. Exclusion Criteria: Please contact site directly for more information Contacts and Locations Go

2015 Clinical Trials

296. 12-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression

symptomatology, or atypical cycle patterns) to make this decision. Pregnant participants Unwilling or unable to taper any current antidepressant therapy Participants currently breastfeeding Female not practicing a reliable form of birth control (condom, intrauterine device (IUD), Depo-Provera injection) Due to lamotrigine pharmacokinetics, female subjects wishing to commence oral contraceptive therapy (OCT) within 3 months of enrollment date or anticipate discontinuing OCT during study (stable oral

2015 Clinical Trials

297. Alemtuzumab in Combination With Etoposide and Dexamethasone

with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation. Male patients with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, prior to study entry and for at least 3 months after the last dose of study drug. Negative urine pregnancy test and/or serum pregnancy test within 7 days of initiation of therapy. Male patients with female

2015 Clinical Trials

298. Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

weeks at 150 mg IM at week 3 of study enrollment and repeated at week 15. Drug: Depot medroxyprogesterone acetate (DMPA) DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15. Other Name: Depo Provera Experimental: Etonogestrel impant (Eng-Implant) A standard Nexplanon rod Implant will be placed at study week 3. Device: Etonogestrel implant (Eng-Implant) A standard nexplanon rod implant will be placed at study

2015 Clinical Trials

299. Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

to participants who report using a progestin-only method of contraception at Screening, e.g., Depo-Provera or levonorgestrel-releasing IUD nor to participants using continuous combination oral contraceptive pills, as the absence of regular menstrual cycles is an expected, normal consequence in this context. At Screening, participant states a willingness to refrain from inserting any non-study vaginal products or objects into the vagina, including, but not limited to, spermicides, female condoms, diaphragms

2015 Clinical Trials

300. Regulation of Cervical Mucus Secretion

prescribed in the experimental protocol No objections to taking study drugs No objections to refraining from intercourse the night before any sampling and willing to using condoms during vaginal intercourse. Exclusion Criteria: Oral contraceptive use or other hormone supplement within the preceding 2 months Women with current cervical infection Evidence of abnormal cervical cytology Use of Paragard IUD for contraception Long-acting hormonal contraceptive use in the past 12 months (e.g., Depo-Provera®

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>